Print Page | Sign In | Join ISSX
ISSX Webinar: Ozanimod Metabolism – Qualification of Disproportionate Metabolites
Register Tell a Friend About This EventTell a Friend
ISSX Webinar: Ozanimod Metabolism – Qualification of Disproportionate Metabolites

Ozanimod is a once-daily oral immunomodulator that selectively targets sphingosine 1-phosphate 1 (S1P1) and S1P5 and is approved in the US and EU for the treatment of relapsing forms of multiple sclerosis. Full characterization of drug metabolic pathways and enzymes involved in metabolism is important for understanding clinical safety and efficacy profile of the molecule.

 Export to Your Calendar 10/1/2020
When: October 1, 2020
11:00 AM ET
Where: Online Webinar


Online registration is available until: 10/1/2020
« Go to Upcoming Event List  

Ozanimod is a once-daily oral immunomodulator that selectively targets sphingosine 1-phosphate 1 (S1P1) and S1P5 and is approved in the US and EU for the treatment of relapsing forms of multiple sclerosis. Full characterization of drug metabolic pathways and enzymes involved in metabolism is important for understanding clinical safety and efficacy profile of the molecule. In vitro and in vivo studies were conducted to characterize the metabolism and identify the pathways and enzymes involved in the metabolism. The unique metabolic aspects of ozanimod and characterization and qualification of disproportionate metabolites in safety species will be discussed.

 

Registration:

ISSX Members: ISSX Members attend all ISSX Webinars at no charge! To complete a member registration, please register here.

Non-Members: Please select the "Register" link above to complete your webinar registration.